2016 News Releases

Date Title   12/19/16 Lombard Medical and MicroPort Scientific Corporation Announce Strategic Partnership and Investment Agreement OXFORDSHIRE, England & SHANGHAI--(BUSINESS WIRE)--Dec. 19, 2016-- Lombard Medical, Inc. (NASDAQ: EVAR), a medical device company focused on endovascular aneurysm repair, and MicroPort Scientific Corporation (HK: 0853), a leading global manufacturer and marketer of a diversified portfolio of medical devices, today announced a strategic partnership and a significant infusion of capital into Lombard Medical by MicroPort. This partnership will allow Lomb...  12/05/16 Positive Long-Term Data for Lombard Medical’s Aorfix™ Endovascular Stent Graft System Confirms Sustained Performance in the Most Challenging Anatomies OXFORDSHIRE, United Kingdom, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced positive long-term data for its Aorfix™ endovascular stent graft system providing confirmation of sustained performance in the most challenging anatomies.  The data from the only IDE study to focus on high neck angulation was presented at the 43rd annual VEITHsymposium™ o...  11/21/16 Multi-Centre Early Experience and Data Presented on Lombard Medical’s Altura® Endovascular Stent Graft at the 43rd Annual VEITHsymposium™ UK - Manchester Group of Hospitals presented early experience and 100% technical success in 24 patients treated with Altura OXFORDSHIRE, United Kingdom, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that its Altura® endovascular stent graft system was featured in a scientific presentation at the 43rd annual VEITHsymposium™ in New York City on N...  11/15/16 Lombard Medical Receives NASDAQ Notice of Bid Price Deficiency No Immediate Effect on Listing – EVAR Has 180 Days to Regain Compliance OXFORDSHIRE, United Kingdom, Nov. 15, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Repair (EVAR) of abdominal aortic aneurysms (AAAs), reported that on November 9, 2016, it received a NASDAQ Staff Deficiency Letter indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5450(a)(...  11/14/16 Lombard Medical Announces Scientific Presentations on Aorfix™ and Altura® Endovascular Stent Grafts at the 43nd Annual VEITHsymposium™ Debut of Data on New IntelliFlex™ Delivery System and Clinical Experience with Altura OXFORDSHIRE, United Kingdom, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that both of its endovascular stent grafts for AAA repair, Aorfix™ and Altura®, will be featured in scientific presentations at the 43rd annual VEITHsymposium™.  Aorfix is the first and...  10/27/16 Lombard Medical Reports 2016 Third Quarter, Nine-Month Financial Results IRVINE, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), today reported financial results for the third quarter and nine months ended September 30, 2016. Financial Results For the 2016 third quarter, global revenue was $3.0 million as compared to $4.2 million in the same prior year period.  For the first nine months of 2016, global revenue was $9.8 mi...  08/22/16 Lombard Medical Reports 2016 Second Quarter, Six-Month Financial Results and Provides Update on Strategic Initiatives Commercial Restructuring Shifts Focus Exclusively to Europe, Japan and Key International Markets; Announces Process to Explore Strategic Alternatives  to Maximize Shareholder Value IRVINE, Calif., Aug. 22, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), today reported financial results, provided business highlights for the second quarter and six months ended June 30, 201...  08/12/16 Lombard Medical Reschedules 2016 Second Quarter, Six-Month Financial Results Release and Conference Call Date to August 22 to Provide Complete Information on Operational Initiatives IRVINE, Calif., Aug. 12, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that it has rescheduled the date to report its 2016 Second Quarter, Six-Month Financial Results to Monday, August 22, 2016, in order to provide complete information on operational initiatives that are underway, but will not be fully implemented until next week.  In addition to details o...  08/08/16 Lombard Medical Announces 2016 Second Quarter, Six-Month Financial Results Release and Conference Call Date IRVINE, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that it will release its 2016 second quarter and six-month financial results after the market closes on Monday, August 15, 2016.  In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Monday, August 15, 2016, ...  07/06/16 Lombard Medical Expands European Launch of its New Altura® Endograft System Multiple Patients Successfully Treated with Altura in the Netherlands and Spain IRVINE, Calif., July 06, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that it had expanded the European launch of its revolutionary new Altura® Endovascular stent graft system to the Netherlands and Spain.  On July 4, 2016, Professor Clark J. Zeebregts, Dr. Paul M. van Scha...  06/30/16 Lombard Medical Announces First Commercial Use of its New IntelliFlex™ LP Delivery System for the Aorfix™ Abdominal Aortic Aneurysm Endovascular Stent Graft IntelliFlex LP’s Lower Catheter Profile Expands Aorfix Treatment to More Patients IRVINE, Calif., June 30, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that on June 28, 2016, the first commercial use of its new IntelliFlex™ Low Profile (LP) Delivery System took place to implant the Aorfix™ Endovascular Stent Graft.  The procedure was completed by Dr. N...  06/20/16 Lombard Medical Announces CE Mark Approval for IntelliFlex™ LP Delivery System for the Aorfix™ Abdominal Aortic Aneurysm Endovascular Stent Graft New, Innovative Design Enhances Control and Precision During Placement with the Potential to Reduce Vessel Trauma IRVINE, Calif., June 20, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that it has received CE Mark approval for its IntelliFlex™ Low Profile (LP) Delivery System for the Aorfix™ Endovascular Stent Graft.  This new and innovative system will...  06/16/16 Lombard Medical to Initiate the Altura® ALTITUDE Global Registry to Evaluate the Treatment of Abdominal Aortic Aneurysms Across a Wide Range of “Real-World” Endovascular Aneurysm Repair Interventions Paul Hayes, MD, FRCS, Endovascular Surgeon, University of Cambridge and Addenbrookes Hospital, Appointed as Principal Investigator IRVINE, Calif., June 16, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced plans to conduct a 1,000 patient global registry to evaluate its new Altura® Endograft System. The ALTITUDE registry (ALTura Impact on the Treatment of A...  06/13/16 Lombard Medical Reports Positive Five-Year Aorfix™ Endovascular Stent Graft Clinical Results in AAA Patients with Challenging Anatomy Aorfix Remains the Only Global On-Label Solution for Tortuous AAA Anatomy IRVINE, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced positive clinical results from The Prospective Aneurysm Trial: High Angle Aorfix™ Bifurcated Stent Graft (PYTHAGORAS trial) at the 2016 Society for Vascular Surgery Annual Meeting in National Harbor, Maryland....  06/08/16 Lombard Medical Provides Update on Controlled Launch of the New Altura® Endovascular Stent Graft in Europe Controlled Launch Expanded to 37 Centers in the UK and Germany IRVINE, Calif., June 08, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced the following commercial update of the new Altura® Endovascular Stent Graft System. Altura Endovascular Stent Graft procedures have been completed in 27 centers since commercial launch in late February in the UK an...  06/07/16 Lombard Medical to Present at the Jefferies 2016 Healthcare Conference IRVINE, Calif., June 07, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that CEO Simon Hubbert is scheduled to present at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016, at 4:00 pm ET in New York City. A live audio webcast may be accessed in Events and Presentations of the Investors section of Lombard’s website at www.lombardmedica...  06/06/16 Lombard Medical Receives Australian Therapeutic Goods Administration (TGA) Approval for the Aorfix™ Endovascular Stent Graft for the Treatment of Abdominal Aortic Aneurysms IRVINE, Calif., June 06, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that the Australian Therapeutic Goods Administration (TGA) has approved the Aorfix™ Endovascular Stent Graft for inclusion on the Australian Register of Therapeutic Goods.  The TGA has approved the use of Aorfix for the treatment of abdominal aortic aneurysms (AAAs) with aortic neck a...  06/02/16 Lombard Medical Announces Scientific Presentation on Aorfix™ Endovascular Stent Graft Five-Year Clinical Data at the 2016 Society for Vascular Surgery Annual Meeting IRVINE, Calif., June 02, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that its Aorfix™ Endovascular Stent Graft will be featured in a scientific presentation at the 2016 Vascular Annual Meeting of the Society for Vascular Surgery (SVS) to be held at the Gaylord National Resort & Convention Center in National Harbor, Maryland, June 8-11, 2016.  Aorfi...  05/31/16 Lombard Medical Announces Scientific Presentation by Leading Japanese Surgeons on Improving Endovascular Aneurysm Repair (EVAR) Treatment using the Aorfix™ Endovascular Stent Graft at the 2016 Japanese Society for Vascular Surgery Annual Meeting in Tokyo, Japan IRVINE, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that its Aorfix™ Endovascular Stent Graft was featured in a scientific presentation on May 25, 2016, at the 2016 Japanese Society for Vascular Surgery Annual Meeting held in Tokyo, Japan.  Aorfix is the first and only endovascular stent graft with global approvals for the treatment of ...  05/19/16 Lombard Medical Announces Scientific Presentation on Altura® and Aorfix™ Endovascular Stent Grafts at the International Symposium on Endovascular Therapeutics, SITE Update 2016 Broader European Launch Planned for New Altura Endovascular Stent Graft IRVINE, Calif., May 19, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that both of its endovascular stent grafts for AAA repair, Altura® and Aorfix™, were featured in a scientific presentation at the International Symposium on Endovascular Therapeutics, SITE Update held on May 13, 2...  05/17/16 Lombard Medical Releases Positive Early Results from the Altura® Endograft System Clinical Evaluation IRVINE, Calif., May 17, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced the 30-day clinical results on 57 patients that were implanted with the Altura® Endograft System.  The 57 patients were implanted by Albrecht Krämer, MD at the Pontificia Universidad Católica de Chile Hospital in Santiago, Chile, and Dainis Krievins, MD, PhD, Professor & Department...  05/11/16 Lombard Medical Reports 2016 First Quarter Financial Results IRVINE, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), today reported financial results and provided an operational update for the first quarter ended March 31, 2016. Q1 and Recent Operational Highlights Initiated a controlled commercial launch of the new Altura® endovascular stent graft system in Germany and the United Kingdom (UK). The first ...  05/03/16 Lombard Medical Announces 2016 First Quarter Financial Results Release and Conference Call Date IRVINE, Calif., May 03, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that it will release its 2016 first quarter financial results after the market closes on Wednesday, May 11, 2016.  In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Wednesday, May 11, 2016, to discuss finan...  04/21/16 Lombard Medical Announces Scientific Presentations on Altura® and Aorfix™ Endovascular Stent Grafts at the 38th Annual Charing Cross International Symposium Company exhibit to include a ‘hands-on’ learning center for new Altura Endovascular Stent Graft and Aorfix with the IntelliFlex LP Delivery System IRVINE, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that both of its endovascular stent grafts for AAA repair, Altura® and Aorfix™, will be featured in scientific presentations at the 38th...  04/14/16 Lombard Medical Completes First Altura® Endovascular Stent Graft Live Case Training Workshop for German Physicians IRVINE, Calif., April 14, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that it completed its first Altura® Endovascular Stent Graft Live Case Physician Training Workshop.  The program and live case were led by Dainis Krievins, MD, PhD, Professor & Department Head of Vascular & Endovascular Surgery at the Pauls Stradins Clinical University Hospital in Rig...  04/04/16 Lombard Medical Provides Update on New Altura® Endovascular Stent Graft Launch Launch Reference Centers Continue to be Established in the UK and Germany IRVINE, Calif., April 04, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced an update on the commercial launch of the new Altura® Endovascular Stent Graft.  Since the commercial launch in late February, Altura has been implanted at approximately half of the 20 initial launch reference centers ...  03/09/16 Lombard Medical Completes First Altura® Endovascular Stent Graft Live Case Physician Training Workshop Event Featured Technical Review and Live Case Presentations IRVINE, Calif., March 09, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that the first Altura® Endovascular Stent Graft Live Case Physician Training Workshop was completed on March 7, 2016, by Dainis Krievins, MD, PhD, Professor & Department Head of Vascular & Endovascular Surgery at the Pauls S...  03/03/16 Lombard Medical's New Altura® Endovascular Stent Graft to be Presented at 9th Annual Houston Aortic Symposium Dainis Krievins, MD Will Present at Late Breaking AAA Presentation IRVINE, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that Dainis Krievins, MD, PhD, Professor of Surgery and Vascular Surgery, University of Latvia, will present on the new Altura® Endovascular Stent Graft in a late breaking AAA presentation at the ninth annual Houston Aortic S...  02/26/16 Lombard Medical Receives NASDAQ Notice of Bid Price Deficiency No Immediate Effect on Listing – EVAR Has 180 Days to Regain Compliance IRVINE, Calif., Feb. 26, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Repair (EVAR) of abdominal aortic aneurysms (AAAs), reported that on February 24, 2016, it received a NASDAQ Staff Deficiency Letter indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5450(a)(1) which req...  02/24/16 Lombard Medical Announces First Commercial Altura® Endovascular Stent Graft Procedure in Germany Following LINC Patient Successfully Treated Using the Revolutionary Altura Endovascular Stent Graft IRVINE, Calif., Feb. 24, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that the first commercial procedure in Germany using the revolutionary new Altura® Endovascular Stent Graft was successfully completed at the Saarland University Medical Center-Clinic for Diagnostic and Inter...  02/22/16 Lombard Medical Reports 2015 Fourth Quarter, Full Year Financial Results Global 2015 Revenue Grew by 13.8% Over 2014;  U.S. Revenue for the Year Grew 42.1% Over 2014 IRVINE, Calif., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), today reported financial results and provided an operational update for the fourth quarter and year ended December 31, 2015. As reported in January, full year revenue increased 13.8% over 2014 with total f...  02/16/16 Lombard Medical Announces 2015 Fourth Quarter and Year-End Financial Results Release and Conference Call Date IRVINE, Calif., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that it will release its 2015 fourth quarter and year-end financial results before the market opens on Monday, February 22, 2016.  In conjunction with the release, the Company will host a conference call with the investment community at 10:30 a.m. Eastern Time on Monday, February 22, 20...  02/04/16 Lombard Medical Announces First Commercial Altura® Endovascular Stent Graft Procedure Patient Was Successfully Treated Using the Revolutionary Altura Endovascular Stent Graft IRVINE, Calif., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that the first commercial procedure using the revolutionary new Altura® Endovascular Stent Graft took place on February 3, 2016, at University Hospital of South Manchester (UHSM) in the United Kingdom.  T...  01/27/16 Lombard Medical Announces Completion of Altura® Endovascular Stent Graft Live Case Presentation at the 12th Annual Leipzig Interventional Course (LINC) First Ever Live Case Presentation Highlighted Revolutionary Product Advantages IRVINE, Calif., Jan. 27, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that on January 27, 2016 its new Altura® Endograft System successfully treated a patient with an abdominal aortic aneurysm in a live clinical case presentation for the first time at the 12th annual Leipzig Interven...  01/21/16 Lombard Medical Announces First Ever Altura® Endovascular Stent Graft Live Clinical Case Presentation at the 12th Annual Leipzig Interventional Course (LINC) Scientific Presentations on Aorfix™ and New Altura Stent Graft Systems Also Scheduled IRVINE, Calif., Jan. 21, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that its new Altura® Endograft System for AAA repair will be featured in a live clinical case presentation for the first time at the 12th annual Leipzig Interventional Course (LINC) being held at th...  01/12/16 Lombard Medical Announces 2015 Preliminary Revenue and Refocus of Commercial Organization for 2016 Product Launches IRVINE, Calif., Jan. 12, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced preliminary revenue for its fourth quarter and full year 2015 as well as several key commercial and operational imperatives for the coming year. Preliminary Revenue The Company reported preliminary revenue of $2.9 million for the 2015 fourth quarter and $15.1 million for the 2015 ...